NICE Rejects Keytruda/Inlyta Combo First-Line In RCC
More Mature Evidence Needed Says Draft Guidance
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.